<DOC>
	<DOCNO>NCT01262976</DOCNO>
	<brief_summary>The purpose study assess safety immunogenicity GlaxoSmithKline ( GSK ) Biologicals ' candidate tuberculosis vaccine ( 692342 ) administer Human Immunodeficiency Virus ( HIV ) -positive adult age 18 59 year , live tuberculosis endemic region . Subjects followed-up 3 year . Subjects enrol 3 cohort : - HIV-positive adult highly active antiretroviral therapy - HIV-positive adult highly active antiretroviral therapy - HIV-negative adult Each cohort 2 group .</brief_summary>
	<brief_title>Safety Immunogenicity Study Candidate Tuberculosis Vaccine Human Immunodeficiency Virus ( HIV ) -Positive Adults</brief_title>
	<detailed_description>This Protocol Posting update follow Protocol Amendment 1 , February 2011 , lead update outcome measure inclusion exclusion criterion .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A male female , include , 18 59 year age time first vaccination . Written inform consent obtain subject prior study procedure . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Clinically acceptable laboratory value screen determined investigator . No evidence tuberculosis disease evidence pulmonary pathology confirm chest Xray . No history extra pulmonary tuberculosis . Based medical history , subject must history chemotherapy tuberculosis . Additional inclusion criterion subject enrol HIV+ highly active antiretroviral therapy cohort : Subjects must HIVpositive care physician least 6 month . Subjects must CD4+T cell count &gt; = 250 cells/mm3 screening . Subjects must stable highly active antiretroviral therapy least 6 month , undetectable HIV viral load level screening . Additional inclusion criterion subject enrol HIV+ treatment naïve cohort : Subjects must HIVpositive care physician least 6 month Subjects must highly active antiretroviral therapynaïve ( never receive antiretroviral therapy HIV diagnosis ) Subjects must CD4 + T cell count 350 cells/mm3 screening . Subjects commencement highly active antiretroviral therapy expect base current assessment within next year . Subjects must viral load 5000 80000 copies/mL screening . Additional inclusion criterion subject enrol HIVnegative cohort • Subjects must negative HIV1 . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Administration register live vaccine foreseen study within 30 day precede first dose study vaccine administration register inactivated vaccine within 14 day precede first dose study vaccine . History previous administration experimental Mtb vaccine . History previous exposure component investigational vaccine within 30 day precede first dose study vaccine Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine/product dose . For corticosteroid , mean prednisone &gt; = 20 mg/kg/day , equivalent . Inhaled topical steroid allow . Any condition illness medication , opinion Investigator might interfere evaluation safety immunogenicity vaccine . Planned participation participation another experimental protocol experimental product study period . Administration immunoglobulin , immunotherapy and/or blood product within three month precede first dose study vaccination , plan administration study period . Subjects take follow medication : chronic administration systemic steroid , interleukin , systemic interferon systemic chemotherapy . History allergic reaction anaphylaxis drug vaccine . History allergic disease reaction likely exacerbate component vaccine . History chronic alcohol consumption and/or drug abuse Investigator 's opinion would put subject risk . Pregnant female , lactate female female planning become pregnant stop contraception . Acute chronic clinically relevant pulmonary , cardiovascular , hepatic renal function abnormality determine physical examination laboratory screen test . Additional exclusion criterion subject enrol HIV+ highly active antiretroviral therapy cohort : Any change antiretroviral drug regimen within 12 week prior screen . Any chronic drug therapy , highly active antiretroviral therapy prophylaxis opportunistic HIV related infection , birth control pill , antihistamine seasonal allergy SSRIs .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Tuberculosis vaccine</keyword>
</DOC>